Buscas alternativas:
decrease processes » disease processes (Expandir a busca), decay processes (Expandir a busca), increase process (Expandir a busca)
decrease decrease » decrease release (Expandir a busca), disease decreases (Expandir a busca), decreases disease (Expandir a busca)
decrease docking » decrease during (Expandir a busca), decrease owing (Expandir a busca), decrease lodging (Expandir a busca)
docking receptor » sensing receptor (Expandir a busca), docking center (Expandir a busca)
decrease toc » decrease the (Expandir a busca), decrease on (Expandir a busca), decreased to (Expandir a busca)
toc decrease » to decrease (Expandir a busca), the decrease (Expandir a busca), not decrease (Expandir a busca)
decrease of » decrease in (Expandir a busca)
of decrease » or decrease (Expandir a busca), not decrease (Expandir a busca), to decrease (Expandir a busca)
decrease processes » disease processes (Expandir a busca), decay processes (Expandir a busca), increase process (Expandir a busca)
decrease decrease » decrease release (Expandir a busca), disease decreases (Expandir a busca), decreases disease (Expandir a busca)
decrease docking » decrease during (Expandir a busca), decrease owing (Expandir a busca), decrease lodging (Expandir a busca)
docking receptor » sensing receptor (Expandir a busca), docking center (Expandir a busca)
decrease toc » decrease the (Expandir a busca), decrease on (Expandir a busca), decreased to (Expandir a busca)
toc decrease » to decrease (Expandir a busca), the decrease (Expandir a busca), not decrease (Expandir a busca)
decrease of » decrease in (Expandir a busca)
of decrease » or decrease (Expandir a busca), not decrease (Expandir a busca), to decrease (Expandir a busca)
1
2
3
4
5
6
7
“...Os inibidores do receptor de angiotensina II do tipo 1 (AT1R), fármacos da classe das sartanas...”
Acessar documento
Acessar documento
Dissertação
8
9
10
“... receptor 2 (VEGFR2) inhibition activity. Here, we present the synthesis of new 1-aryl-3-[4-(thieno...”
Acessar documento
Acessar documento
11
12
13
“... genômico da CPB2.8, nos permite utilizar estratégias de planejamento de fármacos baseado no receptor (SBDD...”
Acessar documento
Acessar documento
Tese
14
15
16
17
Assuntos:
“...DFT, Molecular Docking, Cyclodextrin, GROMOS, Central Nervous System...”
Acessar documento
Acessar documento
Tese
18
Assuntos:
“...DFT, Molecular Docking, Cyclodextrin, GROMOS, Central Nervous System...”
Acessar documento
Acessar documento
Tese
19
Assuntos:
“...DFT, Molecular Docking, Cyclodextrin, GROMOS, Central Nervous System...”
Acessar documento
Acessar documento
Tese
20